title: Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer.
abstract: OBJECTIVE
  To report toxicity data from the first 13 consecutive patients with locally advanced head and neck squamous cell carcinoma (LAHNSCC), ineligible for cisplatin, treated with concurrent cetuximab and radiotherapy (RT) at our institution.
  
  
  METHODS
  Data were collected prospectively between August 2007 and May 2008. Planned treatment consisted of a cetuximab loading dose (400mg/m(2)) via intravenous infusion 1 week prior and then weekly (250mg/m(2)) with 70Gy in 35 daily fractions over 7 weeks.
  
  
  RESULTS
  Median age was 68 years (range 52-82 years). The predominant primary sites were hypopharyngeal (5) and oropharyngeal (5). Ineligibility for cisplatin consisted of renal impairment (5), hearing impairment (4) and of other major co-morbidities (4). Of the 13 patients, 10 (77%) had grade 3/4 skin reactions and 10 (77%) grade 3/4 mucositis. Six (46%) patients required admission for management of severe skin reactions and/or mucositis with 4 (31%) requiring a treatment break, median 10 days (9-15days). Only 4 (31%) patients managed to complete the planned 8 cycles of cetuximab. Of the 9 patients with 12-week post-therapy data, 7 (78%) achieved a complete response.
  
  
  CONCLUSIONS
  Our early experience with cetuximab/RT has demonstrated a higher rate of toxicity compared with the recently reported randomised trial, resulting in low treatment compliance and delays in completing RT.
authors.affiliation: Department of Radiation Oncology, Princess Alexandra Hospital, Brisbane, Australia.
authors.forename: David I
authors.initials: DI
authors.lastname: Pryor
authors.forename: Sandro V
authors.initials: SV
authors.lastname: Porceddu
authors.forename: Bryan H
authors.initials: BH
authors.lastname: Burmeister
authors.forename: Alex
authors.initials: A
authors.lastname: Guminski
authors.forename: Damien B
authors.initials: DB
authors.lastname: Thomson
authors.forename: Kristine
authors.initials: K
authors.lastname: Shepherdson
authors.forename: Michael
authors.initials: M
authors.lastname: Poulsen
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000532:radiotherapy*; D000068818:Cetuximab; D003131:Combined Modality Therapy; D003875:Drug Eruptions / Q000209:etiology / Q000473:pathology; D004815:Epidermal Growth Factor / Q000037:antagonists & inhibitors; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010039:Otorhinolaryngologic Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D011855:Radiodermatitis / Q000473:pathology*; D011879:Radiotherapy Dosage
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D004815:Epidermal Growth Factor; D000068818:Cetuximab